These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 15280679

  • 1. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, Williams TJ, Kotsimbos TC.
    Transplantation; 2004 Jul 27; 78(2):205-10. PubMed ID: 15280679
    [Abstract] [Full Text] [Related]

  • 2. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM, Burkett P, Divo M, Keller S, Rosas IO, Trindade A, Mody GN, Singh SK, El-Chemaly S, Camp PC, Goldberg HJ, Mallidi HR.
    Ann Thorac Surg; 2018 Feb 27; 105(2):441-447. PubMed ID: 29223419
    [Abstract] [Full Text] [Related]

  • 3. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun 27; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 4. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M, Husain S, Famure O, Li Y, Kim SJ.
    Prog Transplant; 2019 Jun 27; 29(2):185-193. PubMed ID: 30845885
    [Abstract] [Full Text] [Related]

  • 5. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation.
    Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, Palevsky H, Pietra GG, Tomaszewski JE.
    Surgery; 1996 May 27; 119(5):544-51. PubMed ID: 8619211
    [Abstract] [Full Text] [Related]

  • 6. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J.
    Am J Respir Crit Care Med; 1996 Dec 27; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [Abstract] [Full Text] [Related]

  • 7. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A, Dierickx D, Verbeken EK, Tousseyn T, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verleden GM, Van Raemdonck DE, Vos R.
    Clin Transplant; 2017 Jul 27; 31(7):. PubMed ID: 28383790
    [Abstract] [Full Text] [Related]

  • 8. Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation.
    Harwood JS, Gould FK, McMaster A, Hamilton JR, Corris PA, Hasan A, Gennery AR, Dark JH.
    Pediatr Transplant; 1999 May 27; 3(2):100-3. PubMed ID: 10389130
    [Abstract] [Full Text] [Related]

  • 9. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug 27; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 10. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 11. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Nephrol Dial Transplant; 2012 Jul 27; 27(7):2971-9. PubMed ID: 22273720
    [Abstract] [Full Text] [Related]

  • 12. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 13. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F.
    Virol J; 2011 Sep 05; 8():421. PubMed ID: 21892950
    [Abstract] [Full Text] [Related]

  • 14. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
    Levine SM, Angel L, Anzueto A, Susanto I, Peters JI, Sako EY, Bryan CL.
    Chest; 1999 Nov 05; 116(5):1273-7. PubMed ID: 10559086
    [Abstract] [Full Text] [Related]

  • 15. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W.
    Transplantation; 2007 Feb 27; 83(4):433-8. PubMed ID: 17318076
    [Abstract] [Full Text] [Related]

  • 17. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
    Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR.
    J Heart Lung Transplant; 2002 May 27; 21(5):547-54. PubMed ID: 11983544
    [Abstract] [Full Text] [Related]

  • 18. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 19. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center.
    Angel LF, Cai TH, Sako EY, Levine SM.
    Ann Transplant; 2000 Dec 27; 5(3):26-30. PubMed ID: 11147026
    [Abstract] [Full Text] [Related]

  • 20. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
    Lustberg ME, Pelletier RP, Porcu P, Martin SI, Quinion CD, Geyer SM, Caligiuri MA, Baiocchi RA.
    Transplantation; 2015 Jun 27; 99(6):1220-5. PubMed ID: 25427163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.